Physician profile
Ira J Berman
NPI 1215900261
$2,535.53
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $149 · 2021: $632 · 2022: $1,067 · 2023: $27.91 · 2024: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,303.32 | 2019-2022 | |
| Amarin Pharma, INC. | $220.44 | 2019 | |
| Pfizer INC. | $142.15 | 2021-2024 | |
| Amgen INC. | $133.71 | 2021-2023 | Otezla |
| Lilly USA, LLC | $125.81 | 2019-2024 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $120.52 | 2021-2022 | |
| Ucb, INC. | $108.74 | 2021-2022 | |
| Novo Nordisk INC | $98.20 | 2022 | |
| Leo Pharma INC. | $89.73 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $74.82 | 2021-2022 | |
| Janssen Biotech, INC. | $60.89 | 2022 | |
| Biofrontera INC. | $23.23 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| E.R. Squibb & Sons, L.L.C. | $17.50 | 2022 | |
| Incyte Corporation | $16.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.